What is the purpose of this trial?
This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have distributed over a large area in the body (disseminated). Monoclonal antibodies, such as pembrolizumab, may block tumor or cancer growth in different ways by targeting certain cells. It may also help the immune system kill cancer cells.
Cancer Immunotherapy Trials Network
Start Date: 03/09/2017
End Date: 04/01/2018
Last Updated: 02/22/2018
Study HIC#: 1603017496